Aminoglutethimide therapy for advanced carcinoma of the prostate.
The results of aminoglutethimide treatment of 12 patients with advanced progressive metastatic carcinoma of the prostate are reported. As judged by performance status and analgesic requirements, there were subjective improvements in 75% of the group and side effects were minimal. No consistent objective improvements were observed but decrease in plasma androstenedione and testosterone was associated with subjective improvement in most responders. Mean survival of patients following introduction of aminoglutethimide was 6.5 months. Aminoglutethimide "medical adrenalectomy" appears safe and effective in management of advanced carcinoma of the prostate.